The Supreme Court’s rulings in Mayo, Myriad, Alice and others have left IP practitioners exasperated at how Section 101 is now interpreted by courts and the USPTO.
At the BIO International Convention in Philadelphia last week, David Kappos, partner at Cravath Swaine & Moore, described the situation around 101 as a “state of chaos”, and outlined concerns that investment would not flow to the life science industry as a result.
Also speaking at the convention, former Chief Judge of the Federal Circuit Paul Michel said: “The 101 test is not scientific; it is not rational; it is not systematic. So once you go down the road of accepting the idea that we can have this gut feel test for eligibility or anything else, you are upon the road to doom.”
In response, people are beginning to talk about amending 101. The AIPLA and CPIP have both discussed proposals. Kristin Neuman of MPEG LA and Konstantin Linnik of Nutter McClennen & Fish also noted at the BIO convention that the 101TT group had been founded as a think tank to address the issue, with 16 members from pharma, biotech, molecular DX, BioAg, and BIO. They urged attendees to send them ideas for proposals.
Kappos said this was all positive, but emphasised that the move to amend 101 should be industry agnostic, rather than biotech specific.
“This fix-101 initiative needs to be broad based and cross industry,” he said. “It needs to be about American industry per se not just one industry. The key will be putting life sciences, which are being hurt by it, along with technology, which is also being hurt by it.”
For those that need a refresher, 101 states: “Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.”
Linnik noted that the problem lays more with the Supreme Court’s interpretation of 101, rather than the wording of 101. “So one suggestion was that 101 should just say what it says and add ‘and we mean it!” at the end,” he said.
He gave some other examples of published ideas for amending 101:
- Amending 101 to expressly take out novelty and non-obviousness parts of 101 analysis.
- 100 definitions – “new and useful process, machine, manufacture, or composition of matter”, “law of nature”, “natural product:”, “abstract idea”.
- 282 presumption of validity, defences – presumption of “patent-eligibility”; claim to be assessed as a whole.
Others have suggested harmonizing with European regulations, though Linnik conceded this was unlikely.
Some of these proposals were included in a February blog post by Robert Sachs of Fenwick & West on the widely-read Bilski Blog that listed “22 Ways Congress Can Save Section 101”.
Bob Armitage, former general counsel at Eli Lilly, outlined a proposal for overhauling 101 at the convention. The conclusions from proposal this were:
Armitage conceded that it would take a long time to change 101.
“The best thing I can say today is that we are at the very early stages looking at what can be done,” he said. “The problem is urgent enough that we don’t have 10 years. Hopefully, we can work across these groups and come up with one proposal – although we are probably several hundred drafts away from that one proposal!”
The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.
© 2020 Euromoney Institutional Investor PLC. For help please see our FAQs.